Adlai Nortye 
Welcome,         Profile    Billing    Logout  
 1 Product   98 Diseases  1 Product   9 Trials   161 News 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
buparlisib (AN2025) / Adlai Nortye
BURAN, NCT04338399 / 2019-000790-23: The Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Active, not recruiting
3
483
Europe, Canada, Japan, US, RoW
Buparlisib & Paclitaxel, AN2025
Adlai Nortye Biopharma Co., Ltd.
Head and Neck Cancer
06/25
06/26
2015-003103-27: A clinical trial of Buparlisib for patients who have been diagnosed with HER2 positive breast cancer with brain metastasis, following previous HER2 directed chemotherapy treatment

Ongoing
2
24
Europe
Buparlisib, BKM120, Capsule
University of Liverpool
HER2-positive breast cancer with brain metastasis, HER2-positive breast cancer with brain tumours, Diseases [C] - Cancer [C04]
 
 
2012-002403-18: Clinical trial aiming to evaluate the impact of a new targeted therapy in patients with recurrent or progressive head and neck cancer after standard therapies Etude clinique évaluant l'intérêt d'un traitement par une nouvelle thérapie ciblée chez des patients atteints de cancer de la tete et du cou en échec thérapeutique après thérapies standard

Not yet recruiting
2
76
Europe
BKM120, BKM120, Capsule, hard
Centre Léon Berard, INCA
Patients with metastatic or relapsed head and neck cancer and documented progression or relapse after platin and cetuximab-based chemotherapy (combination or sequential treatment), Patients with metastatic head and neck cancer progressive under standard therapies, Diseases [C] - Cancer [C04]
 
 
LOGIC-2, NCT02159066 / 2013-004552-38: LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Checkmark Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Sep 2015 - Sep 2015: Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Checkmark From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Sep 2015 - Sep 2015: From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Completed
2
158
Europe, Canada, US, RoW
LGX818, MEK162, LEE011, BGJ398, BKM120, INC280
Pfizer
Melanoma
01/23
01/23
2011-002167-23: A phase Ib/II open-label study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic breast cancer. Etude de phase Ib/II évaluant la sécurité et l’efficacité du BKM120 en combinaison avec le lapatinib dans les cancers du sein récidivants, localement avancés ou métastatiques, HER2+ résistants au trastuzumab avec activation de la voie PI3K

Ongoing
1/2
59
Europe
BKM 120, TYVERB, TYVERB
Institut Paoli-Calmettes, Programme Hospitalier de Recherche Clinique (PHRC), Laboratoires Novartis
locally advanced, recurrent and metastatic breast cancer.
 
 
NCT04975958: Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Completed
1
47
US
AN2025, BKM120, AN0025, E7046, Atezolizumab 1200 mg in 20 ML Injection, Tecentriq
Adlai Nortye Biopharma Co., Ltd.
Locally Advanced Solid Tumor
01/25
01/25
Reolysin (pelareorep) / Oncolytics, Andrus Reo
BRACELET-1, NCT04215146: A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - Study

Active, not recruiting
2
48
US
Paclitaxel, Pelareorep, Avelumab
Oncolytics Biotech, PrECOG, LLC.
Breast Cancer Metastatic
08/22
06/25
IRENE, NCT04445844: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, Study

Checkmark Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Dec 2021 - Dec 2021: Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Active, not recruiting
2
25
US
Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012
Mridula George, MD, Incyte Corporation, Oncolytics Biotech, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
06/25
06/25
AMBUSH, NCT05514990: Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, Trial

Recruiting
1/2
42
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
University of Southern California, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
10/25
10/26
REO 019, NCT02514382: Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
1b
14
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Pharmacological Study, Wild-type Reovirus, Reolysin
University of Southern California, National Cancer Institute (NCI), Oncolytics Biotech
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
04/22
04/22
NCT02444546: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Completed
1
6
US
Laboratory Biomarker Analysis, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Wild-type Reovirus, Reolysin
Mayo Clinic, National Cancer Institute (NCI)
Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
07/18
11/22
NCT02101944: Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Checkmark From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Dec 2015 - Dec 2015: From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Completed
1
12
US
Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus
National Cancer Institute (NCI)
Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
05/21
05/24
NCT05519059: Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Completed
1
15
RoW
Pelareorep, Paclitaxel
Adlai Nortye Biopharma Co., Ltd.
Advanced or Metastatic Breast Cancer
09/22
05/23
NCT03605719: Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Checkmark Updated results
Dec 2018 - Dec 2018: Updated results
Completed
1
23
US
Carfilzomib, Kyprolis, PR-171, Dexamethasone, Decadron, Hexadrol, Ozurdex, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pelareorep, Reolysin, Wild-type Reovirus
Emory University, Bristol-Myers Squibb, Oncolytics Biotech, University of Utah, City of Hope Medical Center, Phylogeny, National Cancer Institute (NCI), National Institutes of Health (NIH)
Recurrent Plasma Cell Myeloma
10/22
10/22
palupiprant (AN0025) / Eisai, Adlai Nortye
NCT05191667: AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Suspended
1
32
RoW
AN0025, Paclitaxel, Carboplatin, Radiotherapy
Adlai Nortye Biopharma Co., Ltd.
Esophageal Cancer
12/25
12/25
KEYNOTE 879, NCT04432857: AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Active, not recruiting
1
63
Europe, US
AN0025, E7046, Pembrolizumab, KEYTRUDA®, MK-3475-879
Adlai Nortye Biopharma Co., Ltd., Merck Sharp & Dohme LLC
Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous, Urothelial Carcinoma of the Bladder, Microsatellite Stable (MSS) Colorectal Cancer (CRC), Cervical Cancer
05/24
01/25
NCT05358691: A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Withdrawn
1
24
US
AN0025, Platinum-based chemotherapy, Radiation, Durvalumab
Rutgers, The State University of New Jersey, Adlai Nortye Biopharma Co., Ltd.
Lung Cancer Stage III
12/27
06/28
AN4005 / Adlai Nortye
AN4005X0101, NCT04999384: First in Human, Dose Escalation Study of AN4005

Recruiting
1
31
US, RoW
AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect
Adlai Nortye Biopharma Co., Ltd.
Advanced Solid Tumor, Advanced Lymphoma
08/25
12/25
AN6025 / Adlai Nortye
No trials found
AN6015 / Adlai Nortye, Xiamen Biotime Biotech
No trials found
AN1005 / Adlai Nortye, Xiamen Biotime Biotech
No trials found
AN9015 / Adlai Nortye
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
buparlisib (AN2025) / Adlai Nortye
BURAN, NCT04338399 / 2019-000790-23: The Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Active, not recruiting
3
483
Europe, Canada, Japan, US, RoW
Buparlisib & Paclitaxel, AN2025
Adlai Nortye Biopharma Co., Ltd.
Head and Neck Cancer
06/25
06/26
2015-003103-27: A clinical trial of Buparlisib for patients who have been diagnosed with HER2 positive breast cancer with brain metastasis, following previous HER2 directed chemotherapy treatment

Ongoing
2
24
Europe
Buparlisib, BKM120, Capsule
University of Liverpool
HER2-positive breast cancer with brain metastasis, HER2-positive breast cancer with brain tumours, Diseases [C] - Cancer [C04]
 
 
2012-002403-18: Clinical trial aiming to evaluate the impact of a new targeted therapy in patients with recurrent or progressive head and neck cancer after standard therapies Etude clinique évaluant l'intérêt d'un traitement par une nouvelle thérapie ciblée chez des patients atteints de cancer de la tete et du cou en échec thérapeutique après thérapies standard

Not yet recruiting
2
76
Europe
BKM120, BKM120, Capsule, hard
Centre Léon Berard, INCA
Patients with metastatic or relapsed head and neck cancer and documented progression or relapse after platin and cetuximab-based chemotherapy (combination or sequential treatment), Patients with metastatic head and neck cancer progressive under standard therapies, Diseases [C] - Cancer [C04]
 
 
LOGIC-2, NCT02159066 / 2013-004552-38: LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Checkmark Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Sep 2015 - Sep 2015: Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Checkmark From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Sep 2015 - Sep 2015: From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Completed
2
158
Europe, Canada, US, RoW
LGX818, MEK162, LEE011, BGJ398, BKM120, INC280
Pfizer
Melanoma
01/23
01/23
2011-002167-23: A phase Ib/II open-label study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic breast cancer. Etude de phase Ib/II évaluant la sécurité et l’efficacité du BKM120 en combinaison avec le lapatinib dans les cancers du sein récidivants, localement avancés ou métastatiques, HER2+ résistants au trastuzumab avec activation de la voie PI3K

Ongoing
1/2
59
Europe
BKM 120, TYVERB, TYVERB
Institut Paoli-Calmettes, Programme Hospitalier de Recherche Clinique (PHRC), Laboratoires Novartis
locally advanced, recurrent and metastatic breast cancer.
 
 
NCT04975958: Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Completed
1
47
US
AN2025, BKM120, AN0025, E7046, Atezolizumab 1200 mg in 20 ML Injection, Tecentriq
Adlai Nortye Biopharma Co., Ltd.
Locally Advanced Solid Tumor
01/25
01/25
Reolysin (pelareorep) / Oncolytics, Andrus Reo
BRACELET-1, NCT04215146: A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - Study

Active, not recruiting
2
48
US
Paclitaxel, Pelareorep, Avelumab
Oncolytics Biotech, PrECOG, LLC.
Breast Cancer Metastatic
08/22
06/25
IRENE, NCT04445844: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, Study

Checkmark Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Dec 2021 - Dec 2021: Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Active, not recruiting
2
25
US
Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012
Mridula George, MD, Incyte Corporation, Oncolytics Biotech, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
06/25
06/25
AMBUSH, NCT05514990: Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, Trial

Recruiting
1/2
42
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
University of Southern California, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
10/25
10/26
REO 019, NCT02514382: Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
1b
14
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Pharmacological Study, Wild-type Reovirus, Reolysin
University of Southern California, National Cancer Institute (NCI), Oncolytics Biotech
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
04/22
04/22
NCT02444546: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Completed
1
6
US
Laboratory Biomarker Analysis, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Wild-type Reovirus, Reolysin
Mayo Clinic, National Cancer Institute (NCI)
Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
07/18
11/22
NCT02101944: Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Checkmark From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Dec 2015 - Dec 2015: From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Completed
1
12
US
Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus
National Cancer Institute (NCI)
Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
05/21
05/24
NCT05519059: Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Completed
1
15
RoW
Pelareorep, Paclitaxel
Adlai Nortye Biopharma Co., Ltd.
Advanced or Metastatic Breast Cancer
09/22
05/23
NCT03605719: Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Checkmark Updated results
Dec 2018 - Dec 2018: Updated results
Completed
1
23
US
Carfilzomib, Kyprolis, PR-171, Dexamethasone, Decadron, Hexadrol, Ozurdex, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pelareorep, Reolysin, Wild-type Reovirus
Emory University, Bristol-Myers Squibb, Oncolytics Biotech, University of Utah, City of Hope Medical Center, Phylogeny, National Cancer Institute (NCI), National Institutes of Health (NIH)
Recurrent Plasma Cell Myeloma
10/22
10/22
palupiprant (AN0025) / Eisai, Adlai Nortye
NCT05191667: AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Suspended
1
32
RoW
AN0025, Paclitaxel, Carboplatin, Radiotherapy
Adlai Nortye Biopharma Co., Ltd.
Esophageal Cancer
12/25
12/25
KEYNOTE 879, NCT04432857: AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Active, not recruiting
1
63
Europe, US
AN0025, E7046, Pembrolizumab, KEYTRUDA®, MK-3475-879
Adlai Nortye Biopharma Co., Ltd., Merck Sharp & Dohme LLC
Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous, Urothelial Carcinoma of the Bladder, Microsatellite Stable (MSS) Colorectal Cancer (CRC), Cervical Cancer
05/24
01/25
NCT05358691: A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Withdrawn
1
24
US
AN0025, Platinum-based chemotherapy, Radiation, Durvalumab
Rutgers, The State University of New Jersey, Adlai Nortye Biopharma Co., Ltd.
Lung Cancer Stage III
12/27
06/28
AN4005 / Adlai Nortye
AN4005X0101, NCT04999384: First in Human, Dose Escalation Study of AN4005

Recruiting
1
31
US, RoW
AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect
Adlai Nortye Biopharma Co., Ltd.
Advanced Solid Tumor, Advanced Lymphoma
08/25
12/25
AN6025 / Adlai Nortye
No trials found
AN6015 / Adlai Nortye, Xiamen Biotime Biotech
No trials found
AN1005 / Adlai Nortye, Xiamen Biotime Biotech
No trials found
AN9015 / Adlai Nortye
No trials found

Download Options